Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Pharmaceutical Companies
  4. Allergy Therapeutics
Thumbnail
November 27, 2019

Investors see no end in sight to the misery of hayfever

Twin setbacks for grass pollen allergy projects in development by Asit Biotech and Allergy Therapeutics expose an existential crisis.

Thumbnail
March 18, 2019

Allergy’s lesson: don’t bet on studies that have been delayed

The long overdue readout of a pivotal birch pollen allergy vaccine trial draws a blank for the beleaguered UK company.

Article image
Vantage logo
January 18, 2019

Upcoming events – Allergy's long-awaited birch data and Caladrius's Treg test

Allergy Therapeutics awaits twice-delayed phase III data on its birch pollen project, while Caladrius Biosciences seeks validation of its Treg approach to type 1…

Article image
Vantage logo
July 20, 2018

Upcoming events – FDA decision for Progenics and Allergy comes out of hiding

Progenics hopes to secure US approval for Azedra, while Allergy Therapeutics awaits phase III data with its birch vaccine.

Vantage logo
May 21, 2018

After 11 long years Allergy sees a glimmer of hope

Vantage logo
April 11, 2016

Interview – Allergy Therapeutics sniffs out second chance

Vantage logo
March 18, 2014

Circassia emerges as one of the UK’s most valuable life science companies

Vantage logo
September 17, 2012

EP Vantage Interview – Allergy competition not to be sneezed at

Vantage logo
March 08, 2012

Hay fever vaccines entering new season of innovation

Vantage logo
March 05, 2012

Event – Meda hoping for summer success with hay fever drug

Vantage logo
November 27, 2009

Event – Stallergene’s Europe victory is the start of US ambitions

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.